UPDATE: Piper Jaffray Reiterates Neutral Rating, Lowers PT on Synageva BioPharma Corp.
Posted on January 04, 2013 at 13:59 PM EST
In a report published Friday, Piper Jaffray & Co. reiterated its Neutral rating on Synageva BioPharma Corp. (NASDAQ: GEVA ), but lowered its price target from $57.00 to $53.00. Piper Jaffray noted, “We are incrementally more positive on GEVA following review of the company's S-3 filing which provided us with